10-K · March 5, 2026
Climb Bio (CLYM) is a clinical-stage biotech focused on CD19 (budoprutug) and APRIL (CLYM116) programs for immune-mediated diseases; the 10-K highlights clinical progression (PrisMN Phase 2 FPI Nov 2025, multiple Phase…
Earnings analysis · 10-Q
CLYM earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Climb Bio reported significant improvements in net loss and R&D expenses for Q1 2026. While total revenue figures were not provided, the net loss was reduced to $13.7 million compared to $20.8 million in Q1 2025. The…
Read full summary
Climb Bio reported significant improvements in net loss and R&D expenses for Q1 2026. While total revenue figures were not provided, the net loss was reduced to $13.7 million compared to $20.8 million in Q1 2025. The company achieved a decrease in R&D expenses from $17.3 million to $9.4 million, indicating improved cost management amidst ongoing clinical trials and development efforts for its product candidates.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.2
What stood out
-
Reduced Net Loss
Net loss fell to $13.7 million from $20.8 million year-over-year.
-
Decreased R&D Expenses
R&D expenses decreased significantly from $17.3 million to $9.4 million, indicating better cost management.
-
Strengthened Cash Position
As of March 31, 2026, cash and cash equivalents totaled $146.3 million.
-
Progress on Clinical Trials
Advanced clinical trials for budoprutug with initial data expected in Q4 2026.
-
Private Placement Financing
Raised $110 million through a private placement in April 2026.
-
Regulatory Designation Achievements
Received FastTrack and orphan-drug designations for budoprutug.
What to watch
-
Ongoing Operating Losses
Expect continued significant losses as cash reserves are projected to fund operations into 2028.
-
Dependence on Key Personnel
Disruption in management due to turnover could impede current development projects.
-
Regulatory Approval Risks
Remaining uncertain about the outcome of trials for budoprutug and CLYM116 could delay commercialization.
Management's outlook
Management anticipates continued investment in R&D while managing cash burn.
Earlier filings 4
10-Q · August 12, 2025
Climb Bio reported a much smaller GAAP net loss in Q2 2025 of $(8,666)k (EPS $(0.13)), a large improvement from Q2 2024 net loss of $(54,889)k (EPS $(1.81)). Operating expenses fell to $10,677k this quarter versus…
10-Q · May 14, 2025
Climb Bio reported a net loss of $20.8M (GAAP) or $(0.31) per share for the quarter ended March 31, 2025, driven by a sharp R&D spend ramp. The company holds $29.0M in cash and $168.8M in marketable securities (combined…
10-K · March 25, 2025
Climb Bio positions itself as a clinical-stage, B‑cell focused biotech building a two‑asset pipeline centered on budoprutug (anti‑CD19) and CLYM116 (anti‑APRIL) acquired/licensed via the Tenet acquisition (June 2024)…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.